Itra VX 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itra VX 100 is effective against a range of pathogenic fungi including dermatophytes, yeasts such as Candida species, and molds like Aspergillus species. It is commonly prescribed for conditions such as onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and other systemic and superficial mycoses. The capsule formulation ensures adequate bioavailability and convenient oral administration. Dosage and duration of therapy should be individualized based on the type and severity of infection, as well as patient response. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be carefully evaluated due to itraconazole’s effect on cytochrome P450 enzymes. Regular monitoring of liver function tests is recommended during prolonged therapy. Itra VX 100 Capsule should be used under medical supervision to ensure safety and efficacy.